Q-collar Looks To Help Reduce Brain Injuries
Q30 Innovations has developed the newest solution to reduce the impact of traumatic brain injuries with the creation of the Q-Collar.
The Q-Collar, facilitates the body’s own physiology to create a bubble-wrap effect for the brain, compresses the jugular vein to mildly increase blood volume in the cranium, creating a ‘tighter-fit’ of the brain in the cranium.
This action look assists in reduces the slosh effect – the twisting and slamming of the brain against the skull’s interior walls, which is one cause of mild traumatic brain injury or concussion.
The British Journal of Sports Medicine completed a study on football players at Cincinnati high school in 2015. Each head impact was measured and recorded to study changes in white matter of athletes’ brains.
The study showed that players wearing the the collar had no significant alterations in white matter, whilst athletes not wearing the device showed significant alterations consistent with brain injury. Both groups sustained similar levels of head impacts measured by the helmet-mounted accelerometers worn in all games and practices.
Amir Rosenthal, Performance Sports Group president said: “The results of the studies are compelling and we are very encouraged about the continued effectiveness of the device in testing, first shown in multiple animal studies and now in multiple athlete studies,” said Rosenthal. “We continue to focus our efforts on taking the necessary steps to bring this exciting and promising new product to athletes around the world.”
Tom Hoey, Q-30 Innovations co-founder, added: “These groundbreaking studies show that wearing the device appears to reduce injury to the brain resulting from sports-related blows to the head. These are important findings that warrant continued research of this potential major advance in reducing the occurrence of brain injury, not only in sports, but also for the military and industrial settings.”
The Q-Collar is undergoing additional research and testing and will not be available in the US until it receives approval from the Food and Drug Administration.
